Drugs / MNK-010
last change Jul 2016 re-read 3 minutes ago

MNK-010

Developed for
cancer
Investigated by
Mallinckrodt

Trials 1

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02040558 Jul 2013 → May 2016 cancer Mallinckrodt Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MNK-010 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02040558 ↗
Route Intravenous “Intravenous MNK-010” NCT02040558 ↗